J
James Shearer
Researcher at King's College London
Publications - 73
Citations - 2166
James Shearer is an academic researcher from King's College London. The author has contributed to research in topics: Randomized controlled trial & Cost effectiveness. The author has an hindex of 22, co-authored 61 publications receiving 1930 citations. Previous affiliations of James Shearer include Peninsula College of Medicine and Dentistry & University of Exeter.
Papers
More filters
Journal ArticleDOI
Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence
TL;DR: The authors consider agonist and antagonist pharmacotherapy strategies, preclinical research, including methodological approaches, opioid and nicotine replacement, and agonists for stimulant dependence, and application of agonist-like/replacement strategies, including clinical requirements and risks.
Journal ArticleDOI
Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection.
TL;DR: Retention in MMT was associated with reduced mortality, re-incarceration rates and hepatitis C infection, and prison-based MMT programmes are integral to the continuity of treatment needed to ensure optimal outcomes for individual and public health.
Journal ArticleDOI
A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system
TL;DR: Consideration should be given to the introduction of prison methadone programs particular where community based programs exist for reduced heroin use, syringe sharing and HIV or hepatitis C incidence among prisoners.
Journal ArticleDOI
Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence.
TL;DR: While the improvements were not significant between groups, within-group analysis revealed that the treatment group reduced self-reported cocaine use, reduced criminal activity, reduced cravings, and reduced severity of cocaine dependence.
Journal ArticleDOI
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
James Shearer,Shane Darke,Craig Rodgers,Tim Slade,Ingrid van Beek,John Lewis,Donna Brady,Rebecca McKetin,Richard P. Mattick,A. Wodak +9 more
TL;DR: Modafinil demonstrated promise in reducing methamphetamine use in selected methamphetamine-dependent patients and the study findings support definitive trials of modafInil in larger multi-site trials.